Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,631

Document Document Title
WO/2020/172664A1
Described herein are genetic recognition reagents that bind specifically to a target nucleic acid and comprise terminal left-handed PNA cooperative binding domains that enable concatenation of two or more of the recognition reagents when...  
WO/2020/051207A3
The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presenc...  
WO/2020/156017A1
The present invention relates to a compound represented by formula (I) or a tautomer, optical isomer, deuterated substance, oxynitride, solvate, pharmaceutically acceptable salt or prodrug thereof, a preparation method for the compound, ...  
WO/2020/156437A1
The present invention discloses an AKT inhibitor, and specifically relates to a compound represented by formula I or a pharmaceutically acceptable salt thereof. The present invention further provides a preparation method thereof, and the...  
WO/2020/142612A1
Described herein are pyrido-pyrimidinone and pteridinone compounds or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmace...  
WO/2020/140055A1
Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are u...  
WO/2020/089443A1
The invention relates to crystalline folate salts. The salt consists of a folate anion and an organic cation. The folate anion is 5-methyl-(6S)-tetrahydrofolic acid, and the cation is an organic compound which is an alkanolamine selected...  
WO/2020/092375A1
The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes...  
WO/2020/083089A1
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, a stereoisomer, a solvate, a polymorph, a tautomer, an isotope compound, and a metabolite or a prodrug thereof for treating diseases that ...  
WO/2020/078455A1
The present invention relates to a structurally novel TLR8 (Toll-like receptor 8) agonist and, in particular, to a compound thereof of formula (I), a pharmaceutically acceptable salt and an isomer thereof.  
WO/2020/073906A1
Disclosed is a kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. Also disclosed are a pharmaceutical composition comprising the kinase inhi...  
WO/2020/056714A1
A method for preparing high-purity riboflavin sodium phosphate, comprising: adjusting the pH value to 5.0-7.0; controlling the solution temperature at 20-40℃, and adding an ethanol aqueous solution with a concentration of 95% (ml/ml)...  
WO/2020/051207A2
The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presenc...  
WO/2020/033823A1
The present invention relates to the discovery of novel 2-amino-dihydropteridinone compounds and analogues thereof capable of inhibiting phosphatidylinositol phosphate kinases. In certain embodiments, the compounds of the invention can b...  
WO/2020/007834A1
The present inventionrefers to a crystalline salt comprising5-methyl-(6S)- tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine wherein the molar ratio of -methyl-(6S)-tetrahydrofolic acid to 4-(2-hydroxyethyl)-morpholine is from 1:0.3...  
WO/2020/007839A1
The present inventionrefers to a crystalline salt comprising5-methyl-(6S)-tetrahydrofolic acid L-leucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-leucine ethyl ester is from 1:0.3 to 1:3.0 (in mol/m...  
WO/2020/007841A1
The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester is from 1:0.3 to 1:3.0 (in m...  
WO/2020/007836A1
The present invention is directed to a crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid and L-isoleucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to L-isoleucine ethyl ester is from 1:0.3 to 1:2.0 (...  
WO/2020/007843A1
The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester like L-phenylalanine ethyl ester or L-methionine ethylester, wherein the molar ratio of 5-methyl-(6S)-tetrahyd...  
WO/2019/232120A1
The present invention relates to new pharmaceutical salts and/or co-crystals of sepiapterin which exhibit improved properties. In particular, the invention relates to salts of sepiapterin with improved stability. The invention also relat...  
WO/2019/209757A1
The present invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for reating cellular proliferate disorders (e.g. cancer).  
WO/2019/200120A1
The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.  
WO/2019/178677A1
The present disclosure relates to the targeted delivery of defined active agents and/or immunomodulatory agents to lymph nodes or lipoid cells in a lymphatic tissue. More particularly, the invention provides methods for targeted delivery...  
WO/2019/161963A1
The present invention provides a method of stabilising a biological sample comprising at least two folate species. The method comprises providing the biological sample and contacting the folate species with a reducing agent and an alipha...  
WO/2019/160736A1
The disclosure relates generally to gamma polyglutamated pralatrexate compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated pralatrexate, and methods of making and using the gamma polyglutamated ...  
WO/2019/160734A1
The disclosure relates generally to gamma polyglutamated lometrexol compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated lometrexol, and methods of making and using the gamma polyglutamated lome...  
WO/2019/160735A1
The disclosure relates generally to gamma polyglutamated tetrahydrofolate compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated tetrahydrofolate, and methods of making and using the gamma polyglu...  
WO/2019/160733A1
The disclosure relates generally to gamma polyglutamated methotrexate compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated methotrexate, and methods of making and using the gamma polyglutamated ...  
WO/2019/160732A1
The disclosure relates generally to gamma polyglutamated aminopterin compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated aminopterin, and methods of making and using the gamma polyglutamated am...  
WO/2019/157146A1
The disclosure relates generally to alpha polyglutamated Antifolates, formulations containing liposomes filled with alpha polyglutamated Antifolates, methods of making the alpha polyglutamated Antifolates and liposome containing formulat...  
WO/2019/157138A1
The disclosure relates generally to alpha polyglutamated pemetrexed, formulations containing liposomes filled with alpha polyglutamated pemetrexed, methods of making the alpha polyglutamated pemetrexed and liposome containing formulation...  
WO/2019/157133A1
The disclosure relates generally to alpha polyglutamated raltitrexed, formulations containing liposomes filled with alpha polyglutamated raltitrexed, methods of making the alpha polyglutamated raltitrexed and liposome containing formulat...  
WO/2019/157140A1
The disclosure relates generally to gamma polyglutamated raltitrexed compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated raltitrexed, and methods of making and using the gamma polyglutamated ra...  
WO/2019/157129A1
The disclosure relates generally to alpha polyglutamated pralatrexate, formulations containing liposomes filled with alpha polyglutamated pralatrexate, methods of making the alpha polyglutamated pralatrexate and liposome containing formu...  
WO/2019/157145A1
The disclosure relates generally to gamma polyglutamated pemetrexed compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated pemetrexed, and methods of making and using the gamma polyglutamated peme...  
WO/2019/157121A1
The disclosure relates generally to alpha polyglutamated lometrexol, formulations containing liposomes filled with alpha polyglutamated lometrexol, methods of making the alpha polyglutamated lometrexol and liposome containing formulation...  
WO/2019/157120A1
The disclosure relates generally to polyglutamated alpha tetrahydrofolate compositions, including delivery vehicles such as liposomes containing the polyglutamated alpha tetrahydrofolate, and methods of making and using the polyglutamate...  
WO/2019/157123A1
The disclosure relates generally to alpha polyglutamated aminopterin, formulations containing liposomes filled with alpha polyglutamated aminopterin, methods of making the alpha polyglutamated aminopterin and liposome containing formulat...  
WO/2019/157125A1
The disclosure relates generally to alpha polyglutamated methotrexate, formulations containing liposomes filled with alpha polyglutamated methotrexate, methods of making the alpha polyglutamated methotrexate and liposome containing formu...  
WO/2019/157148A1
The disclosure relates generally to gamma polyglutamated Antifolate, formulations containing liposomes filled with gamma polyglutamated Antifolate, methods of making the gamma polyglutamated Antifolate and liposome containing formulation...  
WO/2019/113685A1
Micelle-forming amphiphilic block copolymers for use in targeting cardiac cells (e.g. fibrotic cells) of a subject suffering from heart failure, micelles containing the micelle-forming amphiphilic block copolymers together with a cardioa...  
WO/2019/111136A1
The present invention relates to a topical pharmaceutical composition containing of about 0.01 % w/w to about 0.1 % w/w of methotrexate in topical solution form for external use for the treatment of psoriasis. The present invention also ...  
WO/2019/076675A1
This invention relates to the finding that the inhibition of solute carrier family 6 member 2 (Slc6a2) exert a sympathomimetic effect outside the brain that promotes weight loss without concomitant hypophagia or hyperkinesia. Compounds f...  
WO/2019/055814A3
Described here are EET analogs conjugated to folate receptor ligands such as folic acid or folic acid analogs recognized by and selectively bound by folate receptors and other folate binding proteins and the use of such conjugated EET an...  
WO/2019/067782A1
Given its various activities in the brain, nitric oxide (NO) has been associated with various neuropsychiatric diseases and/or neuropsychiatric disorders, including schizophrenia. In fact, evidence has been accumulating to show that abno...  
WO/2019/063236A1
The invention relates to amorphous folate salt. The salt consists of a folate anion and an organic cation. The folate anion is selected from the group consisting of 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid,...  
WO/2019/034673A1
The present invention is directed to stable lyophilisates comprising 5,10-methylene-(6R)-tetrahydro folic acid or a pharmaceutically acceptable salt thereof and a dicarboxylic acid, or a salt thereof, as well as, a processes of obtaining...  
WO/2019/029541A1
Provided are a fibroblast growth factor receptor (FGFR) irreversible inhibitor as represented by formula I, a pharmaceutically acceptable salt, a stereoisomer thereof, and pharmaceutical preparations, pharmaceutical compositions and uses...  
WO/2019/016397A1
The invention relates to a compound of formula (I) and to the pharmaceutically acceptable salts thereof. The invention also relates to the use of said compound of formula (I) in the treatment of cancer, particularly by photodynamic therapy.  
WO/2018/229261A1
The invention relates to a prodrug compound consisting of a drug moiety comprising an amine or hydroxyl moiety and a protecting group moiety covalently linked to the amine or hydroxyl moiety. The drug moiety is effective in the treatment...  

Matches 1 - 50 out of 1,631